Am J Transplant, Volume 19, Suppl 3 Archives - Page 193 of 214 - ATC Abstracts

2019 American Transplant Congress
Validation of Gene Expression Signatures Associated with Antibody-Mediated Rejection (ABMR) in Renal Allograft Biopsies (Bx) of HLA-Sensitized Patients
H. Zhang¹, C. C. Nast², N. Ammerman³, A. A. Vo³, S. C. Jordan³, M. Toyoda¹
¹Transplant Immunology Laboratory, Cedars-Sinai Medical Center, Los Angeles, CA, ²Pathology and Laboratory Medicine, Cedars-Sinai Medical Center, Los Angeles, CA, ³Comprehensive Transplant Center, Cedars-Sinai Medical Center, Los Angeles, CA
*Purpose: "Thoroughly validated gene transcripts” in renal Bx was adopted as one of the criteria for ABMR diagnosis in the latest Banff classification. Previously, we…
2019 American Transplant Congress
Predicting Kidney Discards with Donor Admission Text
A. Placona, C. Martinez, B. Carrico
United Network for Organ Sharing, Richmond, VA
*Purpose: Kidney discard rates have increased in part due to technological advancements and deceased donor policy updates that allow for recovery of organs at increased…
2019 American Transplant Congress
Effect of Human Leukocytic Antigen Matching on Clinical Outcomes after Deceased Donor Renal Allograft Transplant: A Single Centre Experience
M. E. Gramlick¹, M. K. Heer², S. Yausis², P. R. Trevillian²
¹Department of Surgery, John Hunter Hospital, Newcastle, Australia, ²Newcastle Transplant Unit, John Hunter Hospital, Newcastle, Australia
*Purpose: Human leucocyte antigen (HLA) matching has been the cornerstone of kidney allocation policies. With increasing expertise in assessing and managing immunological risks, the impact…
2019 American Transplant Congress
Long Term Outcomes in Kidney Transplant Recipients Receiving Everolimus (EVR) or Mycophenolate (MPS) in Combination with Tacrolimus (TAC)
K. Ficher, C. Rosso Felipe, Y. Cardoso Dreige, K. Linhares, A. Ferreira Brígido, S. Stopa, L. Viana, M. Cristelli, P. Gessolo Lins, W. Aguiar, H. Proença, R. Marco, M. Gerbase de Lima, H. Tedesco Silva Junior, J. Medina Pestana
Hospital do Rim, Nephrology Division, EPM - UNIFESP, São Paulo, Brazil
*Purpose: Detailed long-term data comparing the use of EVR or MPS in kidney transplant recipients receiving TAC is lacking.*Methods: This is a 5-years extension analysis…
2019 American Transplant Congress
Combination of Extended-Release Tacrolimus Plus Everolimus Once Daily in De Novo Kidney Transplant Recipients: ER-Tac vs LCPT
G. Spagnoletti, M. P. Salerno, F. De Gennaro, J. Romagnoli, F. Citterio
Surgery, Renal Transplant Unit, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy
*Purpose: Combination of Everolimus (EVR) with Tacrolimus (Tac) permits reduced calcineurin inhibitors exposure and, recently, has been demonstrated safe and effective. Two different once-daily Tacrolimus…
2019 American Transplant Congress
Risk Factors for Initial Sub- and Supra-Therapeutic Tacrolimus Trough Levels in Renal Transplant Recipients
M. Kapugi, K. Cunningham, C. D'Agostino, C. Kane, A. Novak, J. Schulte
Northwestern Memorial Hospital, Chicago, IL
*Purpose: Sub-therapeutic tacrolimus trough levels have been associated with increased risk of rejection in renal transplant recipients and supra-therapeutic levels with infectious risks and drug…
2019 American Transplant Congress
Poor Long-Term Outcome of Liver Transplant Recipients with Preexisting Renal Insufficiency
M. Sterneck¹, M. Touma¹, T. Horvatits², S. Pischke², U. Herden³, A. Lohse², L. Fischer³
¹University Transplant Center, University Medical Center Hamburg Eppendorf, Hamburg, Germany, ²Department of Medicine, University Medical Center Hamburg Eppendorf, Hamburg, Germany, ³Department of Visceral Transplantation, University Medical Center Hamburg Eppendorf, Hamburg, Germany
*Purpose: Due to the MELD based allocation system the number of patients undergoing orthotopic liver transplantation (OLT) with severely impaired renal function has markedly increased.…
2019 American Transplant Congress
Extreme Hyponatremia as a Risk Factor for Early Mortality after Liver Transplantation in the Model for End-Stage Liver Disease-Sodium Period
H. Mouzaihem, M. Safwan, L. C. Chau, D. Moonka, M. Abouljoud, S. Nagai
Transplant and Hepatobiliary Surgery, Henry Ford Hospital, Detroit, MI
*Purpose: While we reported that implementation of MELD-Na based liver allocation improved waitlist outcomes in patients with hyponatremia, its impact on post-transplant outcomes in this…
2019 American Transplant Congress
A Randomized Pilot Trial of Home-Based Physical Activity Plus Dietary Intervention to Improve Physical Function in Patients with Advanced Liver Disease
H. Chen¹, A. A. Ferrando², M. G. White², M. Pauly², T. Bartter², M. A. Dunn¹, W. R. Kim³, A. Duarte-Rojo¹
¹T.E. Starzl Transplantation Institute, University of Pittsburgh Medical Center, Pittsburgh, PA, ²University of Arkansas for Medical Sciences, Little Rock, AR, ³Stanford University, Palo Alto, CA
*Purpose: Deconditioning and frailty are prevalent among liver transplant (LTx) candidates and prehabilitation programs have been proposed in order to improve clinical outcomes. However, few…
2019 American Transplant Congress
Donor Derived Strongyloidiasis, a Preventable Event
R. M. La Hoz¹, G. Vece², L. Danziger-Isakov¹, D. Florescu¹, M. Malinis¹, K. Lilly¹, L. Strasfeld¹, R. P. Wood¹, S. Tlusty², C. R. Wolfe¹, M. G. Michaels¹
¹DTAC, Richmond, VA, ²UNOS, Richmond, VA
*Purpose: In the US, deceased donor screening for Strongyloides started in 2010. By 2013 10% of the OPOs had implemented screening practices. Recipients of sero-positive…